Results-221 patients with symptomatic bacterial vaginosis were enrolled to the study and of these 141 (63.8%) completed the study. On the "intent-to-treat" (ITT) analysis, 75% of the clindamycin group were classified as "success" or "improved" at visit 2 compared with 13% of the placebo group (p < 0.001). At Visit 3, 41% of the clindamycin group were classified as either "success" or "improved" versus 4% in the placebo group (p < 0.001). Of the 80 patients who were recorded "success" or "improved" at visit 2, 20 (25%) were reported to have a "recurrence" of BV at Visit 3. The metaanalysis on those who were evaluable at Visit 2 and 3 also showed that clindamycin cream 2% was an effective treatment for bacterial vaginosis, and the differences between the clindamycin group and the placebo group were statistically significant. Conclusion-We conclude that a 3 day course of clindamycin 2% cream is an effective, and well tolerated treatment for bacterial vaginosis. (Genitourin Med 1995;71:254-256) 
Introduction
Bacterial vaginosis (BV) is considered to be the commonest condition associated with vaginal discharge seen in genitourinary medicine clinics in England.' It is characterised by a fishy-smelling vaginal discharge associated with increased vaginal pH. ' Microscopic examination of a Gram-stained or wet mounted specimen of vaginal secretions shows a characteristic mixed bacterial flora associated with the presence of clue cells (vaginal epithelial cells covered with polymorphic bacteria). Whilst the exact aetiology of this condition remains unknown, BV occurs when the vaginal ecology is altered and the lactobacilli in normal vaginal fluid are replaced by a mixed bacterial flora predominantly consisting of Gardnerella vaginalis, Mobiluncus spp., other anaerobes and Mycoplasma hominis.
Oral metronidazole has been the treatment of choice since Pheifer et al first reported its efficacy in 1978.3 However, relapse rates are high45 and unpleasant side effects and concern about the use of metronidazole in pregnancy have limited its use in some patients.
Clindamycin has proved to be an effective treatment for BV when given orally.6 Good results have also been shown using 2% clindamycin vaginal cream applied twice daily for five days7 or once daily for seven days.8 More recently, a pilot study showed a three day course of 2% clindamycin vaginal cream to be efficacious9 with an 80% cure/improved rate. We conducted this prospective, randomised, double-blind, placebo-controlled study to seek to confirm the results of the pilot study in a multi-centre environment. On the intent-to-treat analysis, 75% of the clindamycin group were classified as "success" or "improved" at visit 2 ME-Failure = medical event failure. 
Patients and methods

Conclusions
We conclude that 5 g clindamycin 2% cream used intravaginally for three days is a well tolerated and effective treatment for BV.
